FMC - North Platte is a medicare approved dialysis facility center in North Platte, Nebraska and it has 17 dialysis stations. It is located in Lincoln county at 785 East Francis, North Platte, NE, 69101. You can reach out to the office of FMC - North Platte at (308) 696-0941. This dialysis clinic is managed and/or owned by Fresenius Medical Care. FMC - North Platte has the following ownership type - Profit. It was first certified by medicare in September, 2003. The medicare id for this facility is 282519 and it accepts patients under medicare ESRD program.
| Name | FMC - North Platte |
|---|---|
| Location | 785 East Francis, North Platte, Nebraska |
| No. of Dialysis Stations | 17 |
| Medicare ID | 282519 |
| Managed By | Fresenius Medical Care |
| Ownership Type | Profit |
| Late Shifts | No |
| 785 East Francis, North Platte, Nebraska, 69101 | |
| (308) 696-0941 | |
News Archive
The battle against AIDS cannot be won in the laboratory alone. To fight the potentially deadly virus that 34 million people are suffering from we need help from computers.
Bioethicists at the Johns Hopkins Berman Institute of Bioethics are co-authors on a consensus article placing "significant responsibility" on biobanks to report individual research results (IRRs) and incidental findings (IFs) to the contributors of genetic material.
StemCells, Inc. announced today that the U.S. Patent and Trademark Office has issued U.S. Patent Number 7,361,505 with broad claims covering human neural stem cells derived from any tissue source, including embryonic, fetal, juvenile, or adult tissue. The ‘505 patent is exclusively licensed to StemCells.
These doctor-patient conversations had been labeled "death panels" by opponents of the Affordable Care Act. Meanwhile, in a bid to reduce backlogs, Medicare offers a deal to hospitals to pay 68 percent of short-term stay medical claims that were rejected by outside auditors.
› Verified 8 days ago
| NPI Number | 1649382458 |
| Organization Name | Renal Care Group North Platte |
| Doing Business As | Rcg North Platte Llc |
| Address | 785 E Francis St North Platte, Nebraska, 69101 |
| Phone Number | (308) 696-0941 |
News Archive
The battle against AIDS cannot be won in the laboratory alone. To fight the potentially deadly virus that 34 million people are suffering from we need help from computers.
Bioethicists at the Johns Hopkins Berman Institute of Bioethics are co-authors on a consensus article placing "significant responsibility" on biobanks to report individual research results (IRRs) and incidental findings (IFs) to the contributors of genetic material.
StemCells, Inc. announced today that the U.S. Patent and Trademark Office has issued U.S. Patent Number 7,361,505 with broad claims covering human neural stem cells derived from any tissue source, including embryonic, fetal, juvenile, or adult tissue. The ‘505 patent is exclusively licensed to StemCells.
These doctor-patient conversations had been labeled "death panels" by opponents of the Affordable Care Act. Meanwhile, in a bid to reduce backlogs, Medicare offers a deal to hospitals to pay 68 percent of short-term stay medical claims that were rejected by outside auditors.
› Verified 8 days ago
| Dialysis patients with Hemoglobin data | 33 |
| Medicare patients who had average hemoglobin (hgb) less than 10 g/dL | 15 |
News Archive
The battle against AIDS cannot be won in the laboratory alone. To fight the potentially deadly virus that 34 million people are suffering from we need help from computers.
Bioethicists at the Johns Hopkins Berman Institute of Bioethics are co-authors on a consensus article placing "significant responsibility" on biobanks to report individual research results (IRRs) and incidental findings (IFs) to the contributors of genetic material.
StemCells, Inc. announced today that the U.S. Patent and Trademark Office has issued U.S. Patent Number 7,361,505 with broad claims covering human neural stem cells derived from any tissue source, including embryonic, fetal, juvenile, or adult tissue. The ‘505 patent is exclusively licensed to StemCells.
These doctor-patient conversations had been labeled "death panels" by opponents of the Affordable Care Act. Meanwhile, in a bid to reduce backlogs, Medicare offers a deal to hospitals to pay 68 percent of short-term stay medical claims that were rejected by outside auditors.
› Verified 8 days ago
Adult patinets who undergo hemodialysis, their Kt/V should be atleast 1.2 and for peritoneal dialysis the Kt/V should be atleast 1.7, that means they are receiving right amount of dialysis. Pediatric patients who undergo hemodialysis, their Kt/V should be atleast 1.2 and for peritoneal dialysis the Kt/V should be 1.8.
Higher percentages should be better.
| Adult patients getting regular hemodialysis at the center | 53 |
| Adult patient months included in Kt/V greater than or equal to 1.2 | 431 |
| Percentage of adult patients getting regular hemodialysis at the center | 96 |
| Percentage of pediatric patients getting regular hemodialysis at the center |
News Archive
The battle against AIDS cannot be won in the laboratory alone. To fight the potentially deadly virus that 34 million people are suffering from we need help from computers.
Bioethicists at the Johns Hopkins Berman Institute of Bioethics are co-authors on a consensus article placing "significant responsibility" on biobanks to report individual research results (IRRs) and incidental findings (IFs) to the contributors of genetic material.
StemCells, Inc. announced today that the U.S. Patent and Trademark Office has issued U.S. Patent Number 7,361,505 with broad claims covering human neural stem cells derived from any tissue source, including embryonic, fetal, juvenile, or adult tissue. The ‘505 patent is exclusively licensed to StemCells.
These doctor-patient conversations had been labeled "death panels" by opponents of the Affordable Care Act. Meanwhile, in a bid to reduce backlogs, Medicare offers a deal to hospitals to pay 68 percent of short-term stay medical claims that were rejected by outside auditors.
› Verified 8 days ago
| Adult patients getting regular peritoneal dialysis at the center | 14 |
| Adult patient months included in Kt/V greater than or equal to 1.7 | 102 |
| Percentage of adult patients getting regular peritoneal dialysis at the center | 97 |
| Percentage of pediatric patients getting regular peritoneal dialysis at the center |
News Archive
The battle against AIDS cannot be won in the laboratory alone. To fight the potentially deadly virus that 34 million people are suffering from we need help from computers.
Bioethicists at the Johns Hopkins Berman Institute of Bioethics are co-authors on a consensus article placing "significant responsibility" on biobanks to report individual research results (IRRs) and incidental findings (IFs) to the contributors of genetic material.
StemCells, Inc. announced today that the U.S. Patent and Trademark Office has issued U.S. Patent Number 7,361,505 with broad claims covering human neural stem cells derived from any tissue source, including embryonic, fetal, juvenile, or adult tissue. The ‘505 patent is exclusively licensed to StemCells.
These doctor-patient conversations had been labeled "death panels" by opponents of the Affordable Care Act. Meanwhile, in a bid to reduce backlogs, Medicare offers a deal to hospitals to pay 68 percent of short-term stay medical claims that were rejected by outside auditors.
› Verified 8 days ago
An important goal of dialysis is to maintain normal levels of various minerals in the body, such as calcium. This shows the percentage of patients treated at FMC - North Platte with elevated calcium levels.
| Patients with hypercalcemia | 63 |
| Hypercalcemia patient months | 539 |
| Patients with Serumphosphor | 70 |
| Patients with Serumphosphor less than 3.5 mg/dL | 12 |
| Patients with Serumphosphor from 3.5 to 4.5 mg/dL | 33 |
| Patients with Serumphosphor from 4.6 to 5.5 mg/dL | 27 |
| Patients with Serumphosphor from 5.6 to 7 mg/dL | 17 |
| Patients with Serumphosphor greater than 7 mg/dL | 11 |
News Archive
The battle against AIDS cannot be won in the laboratory alone. To fight the potentially deadly virus that 34 million people are suffering from we need help from computers.
Bioethicists at the Johns Hopkins Berman Institute of Bioethics are co-authors on a consensus article placing "significant responsibility" on biobanks to report individual research results (IRRs) and incidental findings (IFs) to the contributors of genetic material.
StemCells, Inc. announced today that the U.S. Patent and Trademark Office has issued U.S. Patent Number 7,361,505 with broad claims covering human neural stem cells derived from any tissue source, including embryonic, fetal, juvenile, or adult tissue. The ‘505 patent is exclusively licensed to StemCells.
These doctor-patient conversations had been labeled "death panels" by opponents of the Affordable Care Act. Meanwhile, in a bid to reduce backlogs, Medicare offers a deal to hospitals to pay 68 percent of short-term stay medical claims that were rejected by outside auditors.
› Verified 8 days ago
The arteriovenous (AV) fistulae is considered long term vascular access for hemodialysis because it allows good blood flow, lasts a long time, and is less likely to get infected or cause blood clots than other types of access. Patients who don't have time to get a permanent vascular access before they start hemodialysis treatments may need to use a venous catheter as a temporary access.
| Patients included in arterial venous fistula and catheter summaries | 62 |
| Patient months included in arterial venous fistula and catheter summaries | 372 |
| Percentage of patients getting regular hemodialysis at the center that used an arteriovenous (AV) fistulae for their treatment | 67 |
| Percentage of patients receiving treatment through Vascular Catheter for 90 days/longer | 17 |
News Archive
The battle against AIDS cannot be won in the laboratory alone. To fight the potentially deadly virus that 34 million people are suffering from we need help from computers.
Bioethicists at the Johns Hopkins Berman Institute of Bioethics are co-authors on a consensus article placing "significant responsibility" on biobanks to report individual research results (IRRs) and incidental findings (IFs) to the contributors of genetic material.
StemCells, Inc. announced today that the U.S. Patent and Trademark Office has issued U.S. Patent Number 7,361,505 with broad claims covering human neural stem cells derived from any tissue source, including embryonic, fetal, juvenile, or adult tissue. The ‘505 patent is exclusively licensed to StemCells.
These doctor-patient conversations had been labeled "death panels" by opponents of the Affordable Care Act. Meanwhile, in a bid to reduce backlogs, Medicare offers a deal to hospitals to pay 68 percent of short-term stay medical claims that were rejected by outside auditors.
› Verified 8 days ago
The rate of hospitalization show you whether patients who were being treated regularly at a certain dialysis center were admitted to the hospital more often (worse than expected), less often (better than expected), or about the same (as expected), compared to similar patients treated at other centers.
| Standard Hospitalization Summary Ratio(SHR) Year | January, 2016 - December, 2016 |
| Patients in facility's Hospitalization Summary | 54 |
| Hospitalization Rate in facility | 123 (As Expected) |
| Hospitalization Rate: Upper Confidence Limit | 225.8 |
| Hospitalization Rate: Lower Confidence Limit | 69.9 |
News Archive
The battle against AIDS cannot be won in the laboratory alone. To fight the potentially deadly virus that 34 million people are suffering from we need help from computers.
Bioethicists at the Johns Hopkins Berman Institute of Bioethics are co-authors on a consensus article placing "significant responsibility" on biobanks to report individual research results (IRRs) and incidental findings (IFs) to the contributors of genetic material.
StemCells, Inc. announced today that the U.S. Patent and Trademark Office has issued U.S. Patent Number 7,361,505 with broad claims covering human neural stem cells derived from any tissue source, including embryonic, fetal, juvenile, or adult tissue. The ‘505 patent is exclusively licensed to StemCells.
These doctor-patient conversations had been labeled "death panels" by opponents of the Affordable Care Act. Meanwhile, in a bid to reduce backlogs, Medicare offers a deal to hospitals to pay 68 percent of short-term stay medical claims that were rejected by outside auditors.
› Verified 8 days ago
The rate of readmission show you whether patients who were being treated regularly at FMC - North Platte were readmitted more often (worse than expected), less often (better than expected), or about the same (as expected), compared to similar patients treated at other dialysis centers.
| Standard Readmission Summary Ratio(SRR) Year | January, 2016 - December, 2016 |
| Readmission Rate in facility | 28.8 (As Expected) |
| Readmission Rate: Upper Confidence Limit | 42.4 |
| Readmission Rate: Lower Confidence Limit | 17.5 |
News Archive
The battle against AIDS cannot be won in the laboratory alone. To fight the potentially deadly virus that 34 million people are suffering from we need help from computers.
Bioethicists at the Johns Hopkins Berman Institute of Bioethics are co-authors on a consensus article placing "significant responsibility" on biobanks to report individual research results (IRRs) and incidental findings (IFs) to the contributors of genetic material.
StemCells, Inc. announced today that the U.S. Patent and Trademark Office has issued U.S. Patent Number 7,361,505 with broad claims covering human neural stem cells derived from any tissue source, including embryonic, fetal, juvenile, or adult tissue. The ‘505 patent is exclusively licensed to StemCells.
These doctor-patient conversations had been labeled "death panels" by opponents of the Affordable Care Act. Meanwhile, in a bid to reduce backlogs, Medicare offers a deal to hospitals to pay 68 percent of short-term stay medical claims that were rejected by outside auditors.
› Verified 8 days ago
Hemodialysis treatment requires direct access to the bloodstream, which can be an opportunity for germs to enter the body and cause infection. This information shows how often patients at FMC - North Platte get infections in their blood each year compared to the number of infections expected for the center based on the national average.
| Standard Infection Summary Ratio(SIR) Year | January, 2016 - December, 2016 |
| Infection Rate in facility | .24 (As Expected) |
| SIR: Upper Confidence Limit | 1.17 |
| SIR: Lower Confidence Limit | .01 |
News Archive
The battle against AIDS cannot be won in the laboratory alone. To fight the potentially deadly virus that 34 million people are suffering from we need help from computers.
Bioethicists at the Johns Hopkins Berman Institute of Bioethics are co-authors on a consensus article placing "significant responsibility" on biobanks to report individual research results (IRRs) and incidental findings (IFs) to the contributors of genetic material.
StemCells, Inc. announced today that the U.S. Patent and Trademark Office has issued U.S. Patent Number 7,361,505 with broad claims covering human neural stem cells derived from any tissue source, including embryonic, fetal, juvenile, or adult tissue. The ‘505 patent is exclusively licensed to StemCells.
These doctor-patient conversations had been labeled "death panels" by opponents of the Affordable Care Act. Meanwhile, in a bid to reduce backlogs, Medicare offers a deal to hospitals to pay 68 percent of short-term stay medical claims that were rejected by outside auditors.
› Verified 8 days ago
Patients with anemia require blood transfusions if their anemia is not managed well by their dialysis center. This information shows whether FMC - North Platte's rate of transfusions is better than expected, as expected, or worse than expected, compared to other centers that treat similar patients.
| Standard Transfusion Summary Ratio (STrR) Year | January, 2016 - December, 2016 |
| Patients in facility's Transfusion Summary | 47 |
| Transfusion Rate in facility | 28.9 (As Expected) |
| Transfusion Rate: Upper Confidence Limit | 83.7 |
| Transfusion Rate: Lower Confidence Limit | 11.3 |
News Archive
The battle against AIDS cannot be won in the laboratory alone. To fight the potentially deadly virus that 34 million people are suffering from we need help from computers.
Bioethicists at the Johns Hopkins Berman Institute of Bioethics are co-authors on a consensus article placing "significant responsibility" on biobanks to report individual research results (IRRs) and incidental findings (IFs) to the contributors of genetic material.
StemCells, Inc. announced today that the U.S. Patent and Trademark Office has issued U.S. Patent Number 7,361,505 with broad claims covering human neural stem cells derived from any tissue source, including embryonic, fetal, juvenile, or adult tissue. The ‘505 patent is exclusively licensed to StemCells.
These doctor-patient conversations had been labeled "death panels" by opponents of the Affordable Care Act. Meanwhile, in a bid to reduce backlogs, Medicare offers a deal to hospitals to pay 68 percent of short-term stay medical claims that were rejected by outside auditors.
› Verified 8 days ago
The rate of mortality show you whether patients who were being treated regularly at FMC - North Platte lived longer than expected (better than expected), don’t live as long as expected (worse than expected), or lived as long as expected (as expected), compared to similar patients treated at other facilities.
| Standard Survival Summary Ratio(SIR) Year | January, 2013 - December, 2016 |
| Patients in facility's Survival Summary | 279 |
| Mortality Rate in facility | 16 (As Expected) |
| Mortality Rate: Upper Confidence Limit | 21.5 |
| Mortality Rate: Lower Confidence Limit | 11.7 |
News Archive
The battle against AIDS cannot be won in the laboratory alone. To fight the potentially deadly virus that 34 million people are suffering from we need help from computers.
Bioethicists at the Johns Hopkins Berman Institute of Bioethics are co-authors on a consensus article placing "significant responsibility" on biobanks to report individual research results (IRRs) and incidental findings (IFs) to the contributors of genetic material.
StemCells, Inc. announced today that the U.S. Patent and Trademark Office has issued U.S. Patent Number 7,361,505 with broad claims covering human neural stem cells derived from any tissue source, including embryonic, fetal, juvenile, or adult tissue. The ‘505 patent is exclusively licensed to StemCells.
These doctor-patient conversations had been labeled "death panels" by opponents of the Affordable Care Act. Meanwhile, in a bid to reduce backlogs, Medicare offers a deal to hospitals to pay 68 percent of short-term stay medical claims that were rejected by outside auditors.
› Verified 8 days ago
News Archive
The battle against AIDS cannot be won in the laboratory alone. To fight the potentially deadly virus that 34 million people are suffering from we need help from computers.
Bioethicists at the Johns Hopkins Berman Institute of Bioethics are co-authors on a consensus article placing "significant responsibility" on biobanks to report individual research results (IRRs) and incidental findings (IFs) to the contributors of genetic material.
StemCells, Inc. announced today that the U.S. Patent and Trademark Office has issued U.S. Patent Number 7,361,505 with broad claims covering human neural stem cells derived from any tissue source, including embryonic, fetal, juvenile, or adult tissue. The ‘505 patent is exclusively licensed to StemCells.
These doctor-patient conversations had been labeled "death panels" by opponents of the Affordable Care Act. Meanwhile, in a bid to reduce backlogs, Medicare offers a deal to hospitals to pay 68 percent of short-term stay medical claims that were rejected by outside auditors.
› Verified 8 days ago